Monday, November 9, 2020

Arcturus Therapeutics Gets $220M More In Support For Vaccine Efforts

San Diego-based Arcturus Therapeutics has received up to $220M in additional financial commitments from the country of Singapore, after receiving positive Phase 1/2 study results on one of its compounds. The company said the new manufacturing financial support and potential vaccine purchases up to $220 million from Singapore's Economic Development Board (EDB) came as a result of positive interim clinical study results from its ongoing Phase 1/2 study of ARCT-021, its vaccine candidate for COVID-19. The funding comes in the form of $45 million up front to fund manufacture of ARCT-021 and up to an additional $175 million in vaccine purchases.